BlueRock Therapeutics announces completion of enrolment of Phase 1 trial in patients with Parkinson's disease

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced?the completion of enrolment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson's disease (PD). The purpose of the?Ph1 clinical trial is to evaluate the safety, tolerability, and?preliminary?efficacy?of BRT-DA01 in patients with Parkinson's disease.? Original source: Bayer, website:http://www.bayer.com/, Copyright Bayer AG 2022.
research and development; Parkinson's disease treatments; Bayer; BlueRock [...]